Skip to main content
. 2019 Oct 23;9:1114. doi: 10.3389/fonc.2019.01114

Figure 8.

Figure 8

miR-622 inhibits breast cancer cell EMT, cell viability and migration via RNF8. (A) MDA-MB231 and MCF7 cell was transfected with miR-622 agomir and antagomir respectively. Thirty-six hours after transfection, cells were harvested and lysed to extract total proteins, then western blot assay was performed to detect changes in EMT-related hallmarks (Epithelial status hallmarks: E-cadherin, ZO-1; Mesenchymal status hallmarks: Snail). (B,C) a CCK8 cell vitality assay was performed to detect cell viability capacity of miR-622-overexpressing MDA-MB-231 cell (B) and miR-622-knockd MCF7 cell (C). (D,E) Representative microscopic images and cell counts of migratory cells from the miR-622-mimic (agomir)-transfected MDA-MB-231 breast cancer cell group (D) and the miR-622-inhibitor (antagomir)-transfected MCF7 breast cancer cell group (E) in a Transwell assay; (F,G) Representative microscopic images and a relative distance of wound healing assay in miR-622 overexpressing MDA-MB-231 cells (E) and miR-622 knockdown MCF7 cells (F). Data from the CCK8 cell viability assay, Transwell migration assay and wound healing assay represent the mean ± SEM of three independently prepared samples. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.